[Gastrointestinal symptoms of aclacinomycin A in patients with adult acute nonlymphocytic leukemia--comparison of BH-AC-DMP therapy and BH-AC-AMP therapy].
D015250:Aclarubicin; D000208:Acute Disease; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000600:supply & distribution; D003630:Daunorubicin / Q000600:supply & distribution; D004064:Digestive System / Q000187:drug effects; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage / Q000600:supply & distribution; D009279:Naphthacenes / Q000008:administration & dosage / Q000009:adverse effects; D011239:Prednisolone / Q000008:administration & dosage / Q000600:supply & distribution
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D003561:Cytarabine; D015250:Aclarubicin; D011239:Prednisolone; D015122:Mercaptopurine; D003630:Daunorubicin